Search

Displaying results 461 - 470 of 3387 in total
  1. Target

    Urotensin-2 receptor

    go.drugbank.com/bio_entities/BE0020904
    TargetHumans

    G protein-coupled receptor for the vasoactive neuropeptides urotensin-2 and urotensin-2B (PubMed:14550283).

    Polypeptides: Urotensin-2 receptorSynonyms: Urotensin II receptor, G protein-coupled receptor 14
  2. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated s...

  3. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP).

  4. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    Hyoscyamine is a tropane alkaloid and the levo-isomer of atropine. It is commonly extracted from plants in the Solanaceae or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyami...

    Mixtures: Uta, Uta
  5. Drug

    Sabestomig

    go.drugbank.com/drugs/DB19326
    Investigational

    Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma).

    Synonyms: Immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279) and HAVCR2 (hepatitis A virus cellular receptor 2, T cell immunoglobulin and mucin domains family member
  6. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    ] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on a PD … L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed on anti-PD

  7. Drug

    Sodium fluorophosphate

    go.drugbank.com/drugs/DB09484
    ApprovedInvestigational

    Sodium monofluorophosphate is used in OTC dental preparations to help protect against cavities.

    Mixtures: Luster Premium White AM/PMProducts: Go Smile PM
  8. Drug

    Fazpilodemab

    go.drugbank.com/drugs/DB18924
    Investigational

    Fazpilodemab is under investigation in clinical trial NCT04171765 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-alcoholic Steatohepatitis).

    Synonyms: immunoglobulin G1-kappa, anti-[Homo sapiens KLB (klotho beta, b-Klotho)] and anti-[Homo sapiens FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2)], monoclonal antibody, bispecific; gamma1 heavy chain
  9. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. Scopolamine was first synthesize...

    Mixtures: PB Hyos, Re-PB HyosCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates